Opening “Remyelination in Multiple Sclerosis”
“Remyelination in Multiple Sclerosis”
- Length
- 59 min
- Level
- Undergraduate
- Recorded
- University of Louisville2020
Chapter 1 of 9: Before the lecture
Feng weighs clemastine, opicinumab and high-dose biotin trials against myelin imaging and visual evoked potentials.
Remyelination in multiple sclerosis depends on oligodendrocyte precursor cells, whose numbers and function decline as the disease progresses. Feng, speaking at UofL Neurology Grand Rounds, starts from demyelination as the driver of axonal damage and disability. She then sets out the barriers to repair, including inflammatory environments and cellular debris. Micropillar arrays and rat optic nerve models serve as screens for pro-remyelination compounds, followed by trials of clemastine, opicinumab, temalizumab and high-dose biotin. Magnetization transfer imaging, myelin water imaging and evoked potentials are weighed as trial endpoints, along with crossover designs for detecting small benefits.
Remyelination in multiple sclerosis depends on oligodendrocyte precursor cells, whose numbers and function decline as the disease progresses. Feng, speaking at UofL Neurology Grand Rounds, starts from demyelination as the driver of axonal damage and disability. She then sets out the barriers to repair, including inflammatory environments and cellular debris. Micropillar arrays and rat optic nerve models serve as screens for pro-remyelination compounds, followed by trials of clemastine, opicinumab, temalizumab and high-dose biotin. Magnetization transfer imaging, myelin water imaging and evoked potentials are weighed as trial endpoints, along with crossover designs for detecting small benefits.
Thompson, Lancet. 2018
Rech. N Engl J Med. 2018
Lubetzki. Lancet Neurol. 2020
Frohman. NEJM 354:942, 2006
Expert Rev Neurother. 2019 Oct;19(10):957-1013
Lancet Neurol. 2020 Aug; 1(8): 598-613
This lecture
Talk 105 of 115 of UofL Neurology Grand Rounds.
Choose a node to see how it connects to this lecture. What comes before is on the leftat the top. What comes after is on the rightat the bottom. The ring is what it teaches. People and places are above. Other lectures and books are below.
Press a chosen node again to open it.
Your comment is kept while you sign up.Sign in
Nat Med. 2014 Aug; 20(8): 954–961
Neuropharm. 2010 Sept; 59(3): 149-159
Lancet. 2017 Dec 23;390(10111):2481-2489
Green, Lancet. 2017 Dec 2;390(10112):2485-2489
Cadavel, Lancet Neurol. 2017; 16(3): 189-199; Cadavel, Lancet Neuro: Sep 2019; 18, 9; P845-P856
Diehl, Ther Adv Neurol Disord. 2019; 12: 1756286419863574.
Schwartbach, J Neurol. 2017 Feb;264(2):304-315
Tourbah, Mult Scler. 2016 Nov; 22(13): 1719 - 1731; Cree, Lancet Neurol. 2020 Dec; 19(12): 988-997
Sorensen, Lancet Neurol. 2011 Aug;10(8):691-701; Chataway, Lancet. 2014 Jun;383(9923):1149-67; Eshaghi, PNAS 2019 May; 116 (22): 11020-11027
Scolding, Brain 2017; 140:2779-2794
Brain 2017; 140: 2779–2796
Nat Rev Neurol. 2009;5(5):256–266
Chem Ann Neurol. 2008;63(2):254–262